CoChat

Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis

Open access

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Abstract

Currently, limited information is available to clinicians regarding the long-term efficacy of omalizumab treatment for allergic asthma. In this report, we aimed to (i) systematically review the evidence regarding the long-term efficacy of omalizumab in patients with persistent uncontrolled allergic asthma and to (ii) discuss the cost-effectiveness evidence published for omalizumab in this patient population. A comprehensive search for randomized controlled trials (RCTs; ≥52 weeks) was performed and six studies met our final inclusion criteria (n = 2,749). Omalizumab was associated with significant improvements in quality of life and the Global Evaluation of Treatment Effectiveness. Omalizumab also allowed patients to completely withdraw from inhaled corticosteroid therapy and did not increase the overall incidence of adverse events. However, there was insufficient evidence that omalizumab reduced the incidence of exacerbations and the cost-effectiveness of omalizumab varied across studies. Our data indicated that omalizumab use for at least 52 weeks in patients with persistent uncontrolled allergic asthma was accompanied by an acceptable safety profile, but it lacked effect on the asthma exacerbations. Use of omalizumab was associated with a higher cost than conventional therapy, but these increases may be cost-effective if the medication is used in patients with severe allergic asthma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep08191

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow diagram.
Figure 1 Flow diagram.CC BY · PubMed Central
Figure 2 The effect of omlizumab on asthma exacerbations.
Figure 2 The effect of omlizumab on asthma exacerbations.CC BY · PubMed Central
Figure 3 The effect of omlizumab on the adverse events.
Figure 3 The effect of omlizumab on the adverse events.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Research works printed but not linked: 3

  1. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. <http://www.ncbi.nlm.nih.gov/books/NBK7232/> (2007) Date of access: 20/07/2014.
  2. Bardelas, J., Figliomeni, M., Kianifard, F. & Meng, X. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma. J Asthma 49, 44–52 (2012). · DOI
  3. Lanier, B. Q. et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 91,154–159 (2003). · DOI · Paper page

Cited by

See all 103

Metadata

Authors
Lai, T., Wang, S., Xu, Z., Zhang, C., Zhao, Y., Hu, Y., Cao, C., Ying, S., Chen, Z., Li, W., Wu, B., & Shen, H.
Affiliations
  • Guangdong Medical College (CN)
  • Second Affiliated Hospital of Zhejiang University (CN)
  • State Key Laboratory of Respiratory Disease (CN)
Corresponding author
  • Wu, Bin
  • Shen, Huahao
Venue
Scientific Reports
Published
2015-02-03
Volume
5
Issue
1
Pages
8191-8191
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2019947521
Cited by
103
References
68
Citations by year
2026: 3 · 2025: 2 · 2024: 5 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 14 · 2019: 14 · 2018: 19 · 2017: 15 · 2016: 12 · 2015: 4
FWCI
2.05
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eSpace (Curtin University) (submittedVersion)
Funders
National Natural Science Foundation of China (81370126, 2012BAI05B01)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
omalizumab, allergic asthma, long-term efficacy, drug safety, asthma exacerbations, inhaled corticosteroid withdrawal, quality of life, cost-effectiveness, anti-IgE therapy
MeSH terms
Omalizumab, Age Factors, Asthma, Clinical Trials as Topic, Humans, Severity of Illness Index, Databases, Factual, Treatment Outcome, Anti-Allergic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.